In the News | Charles River
   
 
 
   
   

PET Imaging of Tumor Proliferation
Drug Discovery & Development- March 2010

The Director of Imaging from our Discovery and Imaging Services group had his article entitled “PET Imaging of Tumor Proliferation” published in the March 2010 issue of Drug Discovery & Development. Positron emission tomography (PET) technology strategies have been effectively used in oncology drug research in both the preclinical and clinical stages. The article highlights two PET tracers for oncology that are currently in development, [18F]-3′-deoxy-3′-L-fluorothymidine ([18F]-FLT) and [18F]-1-(29-deoxy-29-fluoro-b-D-arabinofuranosyl) thymine ([18F]-FMAU). The PET tracers discussed are injected intravenously in a patient or research animal and allow for a PET image to be interpreted as a three-dimensional map of cellular proliferation in specific tissues, such as a tumor. The three dimensional map generated with the help of the new tracer candidates discussed will further enhance the value of using PET technology as a tool in assessing efficacy in the preclinical and clinical stages of oncology drug development.

Click here to read the full article.

   
Discover the full range of Charles River Products and Services
The Source

For more information, contact us at:

1.877.CRIVER.1 (1.877.274.8371)
askcharlesriver@crl.com

view all

News & Events

view all
Jan 31 - Discovery PK Now Offered at Charle...
Mar 01 - Drug Discovery & Development: PET ...
May 14 - New Models for Evaluating COPD or ...
Jun 17-Jun 20 -  Noordwijk aan Zee, the Netherlands - 19th MDO Meeting / 12th European ...
Jun 02-Jun 05 - Vancouver, British Columbia - CALAS
Jun 05-Jun 05 - King of Prussia, Pennsylvania - Assessment of Immunomodulation for Biol...
Jun 05-Jun 08 - Saint Germain sur l’Arbresle, France - Charles River LAL Seminar Series
view all
Scientist I Wilmington, MA
Manager International Tax Wilmington, MA

Charles River Laboratories, Inc.